TY  - CHAP
M1  - Book, Section
TI  - Diffuse Large B Cell Lymphoma
A1  - Cummin, Thomas
A1  - Davies, Andrew
A1  - Johnson, Peter W.M.
A2  - Copson, Ellen R
A2  - Hall, Peter
A2  - Board, Ruth E
A2  - Cook, Gordon
A2  - Selby, Peter
PY  - 2018
T2  - Problem Solving Through Precision Oncology
AB  - Diffuse  large  B  cell  lymphoma  (DLBCL)  is  the  commonest  aggressive  non-Hodgkin's  lymphoma,  accounting  for  approximately  4200  new  cases  annually  in  the  UK.1  Standard  of  care  rituximab,  cyclophosphamide,  doxorubicin,  vincristine  and  prednisolone  (R-CHOP)  achieves  cure  in  approximately  60%  of  cases.2  Patients  who  remain  refractory  or  relapse  have  a  poor  outlook:  around  20%  event-free  survival  is  recorded  at  3  years.3  Attempts  to  intensify  chemotherapy  for  high-risk  subgroups  have  so  far  been  unable  to  clearly  recommend  an  improved,  widely  adopted  approach.  Recent  advances  surrounding  molecular  diagnostics  reveal  a  heterogeneous  disease  that  provides  potential  therapeutic  targets  to  improve  outcomes.  DLBCL  will  likely  require  a  personalized  medicine  approach  to  improve  responses  and  survival  for  patients.  Intensified  chemotherapy  regimens  for  high-risk  subgroups,  checkpoint  inhibitors,  monoclonal  antibodies  and  small  molecule  agents  represent  opportunities  to  investigate  and  subsequently  widen  the  armamentarium  against  DLBCL.  Identification  of  predictive  biomarkers  to  direct  therapy  will  be  necessary  to  unpick  the  complexity  of  this  disease  and  guide  subgroups  towards  precision  therapy.  
SN  - 
PB  - Clinical Publishing
CY  - New York, NY
Y2  - 2021/01/27
UR  - hemonc.mhmedical.com/content.aspx?aid=1152360484
ER  -